001067.KS KSC
JW Pharmaceutical Corporation
1W: +1.2%
1M: +4.5%
3M: +18.3%
YTD: -13.4%
1Y: -18.5%
3Y: -12.1%
5Y: -22.0%
₩51,000.00 ($37.91)
+900.00 (+1.80%)
Weekly Expected Move ±3.1%
₩47828
₩49414
₩51000
₩52586
₩54172
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
$96.4B
+21.4% ▲
5Y CAGR: +8.9%
Capital Expenditures
$11.8B
+58.2% ▲
5Y CAGR: -4.8%
Free Cash Flow
$84.6B
+65.1% ▲
5Y CAGR: +12.0%
Dividends Paid
$11.1B
-14.5% ▼
Buybacks
$9.5B
-1171.3% ▼
Net Change in Cash
$28.8B
+625.7% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$1.4B | $29.9B | $35.1B | $65.0B | $58.3B |
| Depreciation & Amort. | $16.1B | $16.8B | $22.6B | $19.1B | $18.7B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$46.1B | -$6.2B | -$20.3B | -$9.3B | $8.4B |
| Other Non-Cash Items | $49.5B | $16.2B | $49.7B | $4.5B | $10.9B |
| Operating Cash Flow | $18.1B | $56.8B | $87.2B | $79.4B | $96.4B |
| — Investing Activities — | |||||
| Capital Expenditures | -$12.9B | -$12.4B | -$43.0B | -$8.3B | -$36.1B |
| Acquisitions (Net) | $385M | -$41M | -$12.0B | -$92M | $45M |
| Investment Purchases | -$140.0B | -$73.8B | -$61.3B | -$155.2B | -$21.7B |
| Investment Sales | $141.1B | $47.5B | $69.6B | $186.9B | $55.7B |
| Other Investing | -$11.4B | $19.8B | -$17.1B | -$9.2B | -$5.2B |
| Investing Cash Flow | -$22.9B | -$18.9B | -$63.8B | $14.1B | -$7.2B |
| — Financing Activities — | |||||
| Net Debt Issuance | $37.0B | -$36.5B | -$28.2B | -$76.5B | -$34.4B |
| Stock Repurchased | -$412M | -$282M | -$261M | -$750M | -$9.5B |
| Dividends Paid | -$7.1B | -$7.4B | -$8.8B | -$9.7B | -$11.1B |
| Other Financing | -$2.6B | -$2.8B | -$3.9B | -$13.3B | -$4.8B |
| Financing Cash Flow | $27.2B | -$36.9B | -$41.2B | -$100.2B | -$59.8B |
| Net Change in Cash | $22.9B | $531M | -$18.0B | -$5.5B | $28.8B |
| Cash End of Period | $33.4B | $33.9B | $15.9B | $10.4B | $39.2B |
| Free Cash Flow | $5.2B | $44.4B | $46.5B | $51.3B | $84.6B |